| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S23560-5mg |
99.4% | ￥300.00 | 6 | - | - | - |
|
S23560-10mg |
99.4% | ￥440.00 | 6 | - | - | - |
|
S23560-25mg |
99.4% | ￥670.00 | 6 | - | - | - |
|
S23560-50mg |
≥98% | ￥1140.00 | 貨期：2-3天 | - | - | - |
|
MYF-01-37 是一種共價 TEAD 抑制劑，靶向 Cys380。MYF-01-37 可逆地抑制 YAP/TEAD 相互作用。
| 產(chǎn)品描述： | MYF-01-37 是一種共價 TEAD 抑制劑，靶向 Cys380。MYF-01-37 可逆地抑制 YAP/TEAD 相互作用。 |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | YAP | ||||||||||||||||||||
| 體外研究： | MYF-01-37 (10 μM; 24h) results in inhibition of direct YAP/TEAD interaction in HEK 293T cells, and in the reduction in canonical YAP target gene CTGF expression in PC-9 cells[1]. MYF-01-37 (0.1, 1, 10, 100 μM) has minimal impact on cell viability of several EGFR-mutant NCSLC cell lines[1]. MYF-01-37 (10 μM; 10 days) combinated with OT (combination of osimertinib and trametinib) leads to a dramatic decrease in dormant cells compared to OT alone[1]. |
||||||||||||||||||||
| 參考文獻： | [1]. Kari J Kurppa, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 Jan 13;37(1):104-122.e12. [Content Brief] | ||||||||||||||||||||
| 溶解性： | DMSO : 250 mg/mL (838.08 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京